Drugmakers resist U.K. price goals

Drug companies are standing their ground in price negotiations with the U.K. government. Pharma is offering to cut the U.K.'s drug bill by roughly half the government's goal, The Daily Telegraph reports. Industry negotiators said they'd reduce the prices of patented drugs by less than 5 percent, when the government was reported to be seeking a 10 percent to 12 percent reduction. To make up some of the difference, drugmakers are saying they'll cut the price of drugs that come off patent but still have little generic competition.

Apparently, the negotiators are at odds over predicted increases in drug costs. Pharma is predicting just 3 percent annual growth, but the government is expecting something like 8 percent, an "insider" told the newspaper.

- read the Telegraph article

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.